The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Key data in sarcoma presented at ASCO 2022
Brian Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, talks on promising new data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including data on NY-ESO-1 for myxoid/round cell liposarcoma and the BMI1 inhibitor unesbulin for the treatment of Ewing sarcoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
